Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention?

Affiliations

Comment

Matthew Butts et al. J Support Oncol. 2010 Jul-Aug.

. 2010 Jul-Aug;8(4):162-3.

No abstract available

Conflict of interest statement

Conflicts of interest: None to disclose

Dermatologic toxicities of targeted anticancer therapies.
Balagula Y, Lacouture ME, Cotliar JA. Balagula Y, et al. J Support Oncol. 2010 Jul-Aug;8(4):149-61. J Support Oncol. 2010. PMID: 20822032 Review.

1. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351–1357. [20142600] - PubMed
1. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13:3913–3921. [17606725] - PubMed
1. Understanding chemotherapy: a guide for patients and families: chemo side effects. American Cancer Society Web site; [Accessed July 16, 2010]. http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/....
1. What I really do: EGFR inhibitor rashes. Global Resource for Advancing Cancer Education (GRACE) Web site; [Accessed July 16, 2010]. http://cancergrace.org/lung/2008/10/22/wird-egfr-rash/